Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9. https://doi.org/10.1002/ajh.25418.

Article  CAS  PubMed  Google Scholar 

Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N Engl J Med. 2024;390(8):22–700. https://doi.org/10.1056/NEJMoa2308917.

Article  Google Scholar 

Mackensen A, Haanen JB, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844–53. https://doi.org/10.1038/s41591-023-02612-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71. https://doi.org/10.1038/s41571-023-00754-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen YJ, Abila B, Mostafa KY. CAR-T: what is next? Cancers (Basel). 2023;15(3):663. https://doi.org/10.3390/cancers15030663.

Article  CAS  PubMed  Google Scholar 

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https://doi.org/10.1038/s41408-021-00459-7.

Article  PubMed  PubMed Central  Google Scholar 

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30. https://doi.org/10.1182/blood-2016-04-703751.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berdeja JG. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. https://doi.org/10.1016/S0140-6736(21)00933-8. (ISSN 0140-6736).

Article  CAS  PubMed  Google Scholar 

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):15–6194. https://doi.org/10.1158/1078-0432.CCR-18-0426.

Article  Google Scholar 

Jacobson CA. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. https://doi.org/10.1016/S1470-2045(21)00591-X. (ISSN 1470-2045).

Article  CAS  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):25–716. https://doi.org/10.1056/NEJMoa2024850.

Article  Google Scholar 

Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020;9(16):5827–38. https://doi.org/10.1002/cam4.3259.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1–1644. https://doi.org/10.1182/blood.2020005278.

Article  Google Scholar 

Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521–9. https://doi.org/10.1016/S2352-3026(19)30115-2. (ISSN 2352-3026).

Article  PubMed  Google Scholar 

Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021;10(3):999–1011. https://doi.org/10.1002/cam4.3686.

Article  CAS  PubMed  Google Scholar 

Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020. https://doi.org/10.1080/2162402X.2020.1846926.

Article  PubMed  PubMed Central  Google Scholar 

Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189–98. https://doi.org/10.1038/s41591-022-01800-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):2–1342. https://doi.org/10.1056/NEJMoa1914347.

Article  Google Scholar 

Xia L, Chen Q, Li Q, Li T, Wang Y, Bao Y. Abstract CT041: The clinical study on CD19-directed chimeric antigen receptor-modified T cells in patient with Richter Syndrome. Cancer Res. 2017;77(13_Supplement):CT041. https://doi.org/10.1158/1538-7445.AM2017-CT041.

Article  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. https://doi.org/10.1016/S1470-2045(18)30864-7.

Article  CAS  PubMed  Google Scholar 

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–74. https://doi.org/10.1200/JCO.22.00842.

Article  CAS  PubMed  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):1–448. https://doi.org/10.1056/NEJMoa1709866.

Article  Google Scholar 

Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-t-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275–84. https://doi.org/10.1200/JCO.22.00690.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–42. https://doi.org/10.1038/s41591-022-01731-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023;24(8):913–24. https://doi.org/10.1016/S1470-2045(23)00222-X.

Article  PubMed  Google Scholar 

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95. https://doi.org/10.1182/blood-2014-05-552729. (Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Erratum in: Blood. 2016 Sep 15;128(11):1533. 10.1182/blood-2016-07-730689).

Article  CAS